RECRUITING

HF Patients With LVADs Being Treated With SGLT2i

Description

The main purpose of this study is to observe outcomes of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in heart failure (HF) patients with left ventricular assist devices (LVAD).

Conditions

Heart Failure With Reduced Ejection Fraction
Talk to us

Related Conditions:

Heart Failure With Reduced Ejection Fraction

Study Overview

On this page

Study Details

Study overview

The main purpose of this study is to observe outcomes of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in heart failure (HF) patients with left ventricular assist devices (LVAD).

Heart Failure Patients With Left Ventricular Assist Devices Being Treated With Sodium-Glucose Co-Transporter 2 Inhibitors

HF Patients With LVADs Being Treated With SGLT2i

Condition
Heart Failure With Reduced Ejection Fraction
Intervention / Treatment

-

Contacts and Locations

Chicago

University of Chicago, Chicago, Illinois, United States, 60637

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. LVAD implantation
  • 2. Have not already been prescribed management with an SGLT2i
  • 3. Estimated glomerular filtration rate (eGFR) ≥ 30 milliliters(ml)/minute(min)/1.73 meter(m)2
  • 4. Age ≥ 18 years-old
  • 5. Able to provide informed consent
  • 1. Diagnosis of Type 1 diabetes mellitus
  • 2. eGFR \< 30 ml/min/1.73 m2
  • 3. Age \< 18 years-old

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Chicago,

Mark Belkin, MD, PRINCIPAL_INVESTIGATOR, University of Chicago

Study Record Dates

2025-06